126 related articles for article (PubMed ID: 18627469)
41. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
42. [The relationship between Candida albicans 25S intron genotypes and antifungal susceptibilities].
Balaban N; Karahan ZC; Mumcuoğlu I; Cayirli A; Kuştimur S
Mikrobiyol Bul; 2007 Apr; 41(2):245-51. PubMed ID: 17682711
[TBL] [Abstract][Full Text] [Related]
43. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
44. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
45. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon.
Dos Santos Abrantes PM; McArthur CP; Africa CW
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):222-7. PubMed ID: 24726686
[TBL] [Abstract][Full Text] [Related]
46. Molecular differentiation and antifungal susceptibility of Candida albicans isolated from patients with respiratory infections in Guiyang Medical College Hospital, China.
Liu Y; Kang Y; Yokoyama K; Gonoi T; Mikami Y
Nihon Ishinkin Gakkai Zasshi; 2009; 50(3):175-8. PubMed ID: 19654451
[TBL] [Abstract][Full Text] [Related]
47. Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait.
Asadzadeh M; Al-Sweih NA; Ahmad S; Khan ZU
Mycoses; 2008 Jul; 51(4):318-23. PubMed ID: 18855844
[TBL] [Abstract][Full Text] [Related]
48. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
Ricardo E; Costa-de-Oliveira S; Dias AS; Guerra J; Rodrigues AG; Pina-Vaz C
FEMS Yeast Res; 2009 Jun; 9(4):618-25. PubMed ID: 19416368
[TBL] [Abstract][Full Text] [Related]
49. [Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalized patients].
Demirbileki M; Timurkaynak F; Can F; Azap O; Arslan H
Mikrobiyol Bul; 2007 Apr; 41(2):261-9. PubMed ID: 17682713
[TBL] [Abstract][Full Text] [Related]
50. Caspofungin-non-susceptible Candida isolates in cancer patients.
Kofteridis DP; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2010 Feb; 65(2):293-5. PubMed ID: 20016020
[TBL] [Abstract][Full Text] [Related]
51. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.
Cross EW; Park S; Perlin DS
Microb Drug Resist; 2000; 6(2):155-61. PubMed ID: 10990271
[TBL] [Abstract][Full Text] [Related]
52. RTA2, a novel gene involved in azole resistance in Candida albicans.
Jia XM; Ma ZP; Jia Y; Gao PH; Zhang JD; Wang Y; Xu YG; Wang L; Cao YY; Cao YB; Zhang LX; Jiang YY
Biochem Biophys Res Commun; 2008 Sep; 373(4):631-6. PubMed ID: 18601908
[TBL] [Abstract][Full Text] [Related]
53. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis].
Kutsyk RV; Pavliuk TD
Mikrobiol Z; 2003; 65(5):26-9. PubMed ID: 14723159
[TBL] [Abstract][Full Text] [Related]
54. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
[TBL] [Abstract][Full Text] [Related]
55. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
Laverdière M; Lalonde RG; Baril JG; Sheppard DC; Park S; Perlin DS
J Antimicrob Chemother; 2006 Apr; 57(4):705-8. PubMed ID: 16464893
[TBL] [Abstract][Full Text] [Related]
56. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
57. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
58. Molecular epidemiology of invasive Candida albicans at a tertiary hospital in northern Taiwan from 2003 to 2011.
Wang SH; Shen M; Lin HC; Sun PL; Lo HJ; Lu JJ
Med Mycol; 2015 Nov; 53(8):828-36. PubMed ID: 26333357
[TBL] [Abstract][Full Text] [Related]
59. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
Balashov SV; Park S; Perlin DS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2058-63. PubMed ID: 16723566
[TBL] [Abstract][Full Text] [Related]
60. Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals.
Ying C; Zhang H; Tang Z; Chen H; Gao J; Yue C
Med Mycol; 2016 May; 54(4):394-9. PubMed ID: 26468549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
